TSTickerStar
Company alerts/GTBP
GTBP company alerts

GTBP updates worth following

TickerStar monitors official filings, investor releases, earnings, and call updates for GTBP. Subscribe to GTBP alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.

Official-source feed

Recent GTBP alert previews

TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.

SEC filingSEC filing

GTBP 10-Q filed 2026-11-16 | Key takeaways

GTBP filed its 10-Q; the most relevant disclosure change is added Reverse Stock Split: On September 8, 2026, the company effectuated a reverse stock-split of its Common Stock at a ratio of 1-for-25. The reverse stock split reduced the number of shares outstanding from 45,109,497 pre-split shares to 1,804,379 post-split shares. The total authoriz.

Read source-backed brief
EarningsOfficial company source

GT Biopharma Reports Third Quarter 2026 Financial Results

GT Biopharma reported a net loss of approximately $3.5 million and a loss from operations of approximately $3.5 million for the quarter ended September 30, 2026. Cash and cash equivalents were approximately $10 million, which the company anticipated would fund operations into Q3 2027. Enrollment continued in Phase 1 trials of GTB-3650 and GTB-5550, with updates anticipated in Q4 2026.

Read source-backed brief
Debt offeringSEC filing

Stockholders approve share authorization and 19.99%-or-more issuance

At its November 11, 2026 Special Meeting, GT Biopharma stockholders approved all four proposals, including elimination of obsolete preferred-stock charter references, an increase in authorized common stock from 25,000,000 to 250,000,000, and approval, for purposes of Nasdaq Rule 5635, of the issuance of 19.99% or more of outstanding common stock in connection with a September 14, 2026 Securities Purchase Agreement, Series M Preferred Stock conversion, and warrant exercises. Stockholders also approved an adjournm...

Read source-backed brief
Debt offeringSEC filing

GT Biopharma files DEF 14A for Special Meeting on Nov. 11, 2026 to approve charter amendments and Series M private placement issuance

GT Biopharma filed a definitive proxy statement for a Special Meeting of Stockholders to be held on November 11, 2026, at 11:00 a.m. Pacific Time in Los Angeles. Stockholders will be asked to approve (i) an amendment and restatement of the Charter to eliminate sections referencing obsolete preferred stock series, (ii) an increase in authorized common stock from 25,000,000 to 250,000,000 shares, (iii) the issuance of 19.99% or more of outstanding common stock in connection with the September 14, 2026 Securities P...

Read source-backed brief